First Trust Advisors LP Invests $360,000 in Lexicon Pharmaceuticals, Inc. (LXRX) Stock

First Trust Advisors LP purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 29,256 shares of the biopharmaceutical company’s stock, valued at approximately $360,000.

A number of other hedge funds also recently made changes to their positions in LXRX. Morgan Stanley increased its position in shares of Lexicon Pharmaceuticals by 22.7% in the first quarter. Morgan Stanley now owns 174,765 shares of the biopharmaceutical company’s stock valued at $2,505,000 after buying an additional 32,276 shares in the last quarter. Credit Suisse AG increased its position in shares of Lexicon Pharmaceuticals by 27.5% in the first quarter. Credit Suisse AG now owns 92,548 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 19,978 shares in the last quarter. Pictet Asset Management Ltd. increased its position in shares of Lexicon Pharmaceuticals by 10.4% in the second quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 6,400 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 0.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 193,318 shares of the biopharmaceutical company’s stock valued at $3,181,000 after buying an additional 1,633 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $2,365,000.

LXRX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Wedbush reissued an “outperform” rating and set a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Finally, ValuEngine lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $28.50.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded up $0.24 on Tuesday, reaching $10.12. The company had a trading volume of 615,727 shares, compared to its average volume of 559,600. Lexicon Pharmaceuticals, Inc. has a 1 year low of $8.07 and a 1 year high of $18.00. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09. The firm has a market cap of $1,070.00, a price-to-earnings ratio of -7.97 and a beta of 0.08.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same quarter in the prior year, the business earned ($0.35) EPS. Lexicon Pharmaceuticals’s revenue was down 2.8% on a year-over-year basis. research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -1.38 earnings per share for the current year.

In other news, CEO Lonnel Coats bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $9.91 per share, with a total value of $99,100.00. Following the transaction, the chief executive officer now directly owns 42,985 shares in the company, valued at $425,981.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Public Equities L.P. Invus bought 145,680 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $9.74 per share, with a total value of $1,418,923.20. The disclosure for this purchase can be found here. In the last quarter, insiders bought 914,353 shares of company stock worth $8,916,253. Company insiders own 5.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.truebluetribune.com/2018/01/03/first-trust-advisors-lp-invests-360000-in-lexicon-pharmaceuticals-inc-lxrx.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply